[go: up one dir, main page]

DK3251699T3 - Sammensætning omfattende methylphenidat og ondansetron til anvendelse i stofrelaterede forstyrrelser - Google Patents

Sammensætning omfattende methylphenidat og ondansetron til anvendelse i stofrelaterede forstyrrelser Download PDF

Info

Publication number
DK3251699T3
DK3251699T3 DK16743696.3T DK16743696T DK3251699T3 DK 3251699 T3 DK3251699 T3 DK 3251699T3 DK 16743696 T DK16743696 T DK 16743696T DK 3251699 T3 DK3251699 T3 DK 3251699T3
Authority
DK
Denmark
Prior art keywords
methylphenidate
ondansetron
substance
composition
related disorders
Prior art date
Application number
DK16743696.3T
Other languages
English (en)
Inventor
Tong Hyon Lee
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of DK3251699T3 publication Critical patent/DK3251699T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
DK16743696.3T 2015-01-28 2016-01-28 Sammensætning omfattende methylphenidat og ondansetron til anvendelse i stofrelaterede forstyrrelser DK3251699T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562108616P 2015-01-28 2015-01-28
PCT/KR2016/000903 WO2016122218A2 (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
DK3251699T3 true DK3251699T3 (da) 2024-05-21

Family

ID=56544502

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16743696.3T DK3251699T3 (da) 2015-01-28 2016-01-28 Sammensætning omfattende methylphenidat og ondansetron til anvendelse i stofrelaterede forstyrrelser

Country Status (8)

Country Link
US (4) US20170326127A1 (da)
EP (2) EP4385575A3 (da)
JP (4) JP6655090B2 (da)
KR (6) KR20220071297A (da)
CN (2) CN114146088A (da)
DK (1) DK3251699T3 (da)
ES (1) ES2985064T3 (da)
WO (1) WO2016122218A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200375957A1 (en) * 2017-04-24 2020-12-03 Chase Therapeutics Corporation Compositions and method for treating depression
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
KR102176538B1 (ko) 2019-01-31 2020-11-09 한국과학기술연구원 항정신병성 약물 검출용 fret 바이오센서 및 이를 이용한 검출 방법
CA3210839A1 (en) * 2021-03-06 2022-09-15 Matthias Emanuel LIECHTI Using geno- or phenotyping to adjust lsd dosing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
KR19990028983A (ko) * 1995-07-14 1999-04-15 피터 제이. 코젠스 디-트레오-메틸페니데이트 및 다른 약품으로 이루어진 조성물
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
US20030114475A1 (en) * 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
EP1587789B1 (en) * 2003-01-16 2008-09-03 Acadia Pharmaceuticals Inc. Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
KR20070087678A (ko) * 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
US7686560B2 (en) * 2005-12-08 2010-03-30 Conestoga Cold Storage Rack, conveyor and shuttle automated pick system
WO2007134077A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP3085231A1 (en) * 2008-05-27 2016-10-26 Intra-Cellular Therapies, Inc. Method and compositions for sleep disorders and other disorders
MX2011001384A (es) * 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders

Also Published As

Publication number Publication date
JP7594045B2 (ja) 2024-12-03
KR20190077590A (ko) 2019-07-03
ES2985064T8 (en) 2025-03-07
US12311056B2 (en) 2025-05-27
KR20220071297A (ko) 2022-05-31
JP2020075938A (ja) 2020-05-21
CN114146088A (zh) 2022-03-08
EP4385575A2 (en) 2024-06-19
JP6655090B2 (ja) 2020-02-26
EP3251699B1 (en) 2024-04-17
KR20180015302A (ko) 2018-02-12
JP6943994B2 (ja) 2021-10-06
KR20160103548A (ko) 2016-09-01
JP2018503677A (ja) 2018-02-08
US20200197383A1 (en) 2020-06-25
US20170326127A1 (en) 2017-11-16
ES2985064T3 (es) 2024-11-04
US20250255823A1 (en) 2025-08-14
EP3251699A2 (en) 2017-12-06
KR20200032759A (ko) 2020-03-26
WO2016122218A2 (ko) 2016-08-04
JP7288016B2 (ja) 2023-06-06
EP3251699A4 (en) 2018-08-01
WO2016122218A3 (ko) 2016-10-13
EP4385575A3 (en) 2024-08-28
US20230293443A1 (en) 2023-09-21
CN107206093A (zh) 2017-09-26
JP2023109947A (ja) 2023-08-08
KR20210095734A (ko) 2021-08-02
JP2021193118A (ja) 2021-12-23
KR101994596B1 (ko) 2019-06-28

Similar Documents

Publication Publication Date Title
SI3215601T1 (sl) Postopki za transdukcijo in obdelavo celic
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3108009T3 (da) Fremgangsmåder og sammensætninger til DNA-profilering
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3256218T3 (da) Kdm1a-hæmmer og anvendelse deraf i terapi
DK3177640T3 (da) Pd-1-midler med høj affinitet og anvendelsesfremgangsmåder
DK2912940T3 (da) Sammensætninger og fremgangsmåder til peronospora-resistens i spinat
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3102189T3 (da) Sammensætning og fremgangsmåde til at fremme søvn
GB201501662D0 (en) Improvements in and relating to horseshoes
DK3319612T3 (da) Oxysteroler og fremgansmåder til anvendelse derfor
DK3324932T3 (da) Sammensætninger og fremgangsmåder for nanopartikel lyofile former
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3065771T3 (da) Fremgangsmåder og sammensætninger til vedvarende immunterapi
DK3177608T3 (da) Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
DK3220750T3 (da) Oral rehydreringssammensætning og fremgangsmåder dertil
DK3233111T3 (da) Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3212776T3 (da) Sammensætninger og fremgangsmåder i forbindelse med beta-glucosidase
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf